Engineered materials for in vivo delivery of genome-editing machinery S Tong, B Moyo, CM Lee, K Leong, G Bao Nature Reviews Materials 4 (11), 726-737, 2019 | 167 | 2019 |
Breast cancer: current developments in molecular approaches to diagnosis and treatment JA de la Mare, L Contu, M C Hunter, B Moyo, J N Sterrenberg, ... Recent patents on anti-cancer drug discovery 9 (2), 153-175, 2014 | 70 | 2014 |
ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells T Scott, B Moyo, S Nicholson, MB Maepa, K Watashi, A Ely, MS Weinberg, ... Scientific reports 7 (1), 7401, 2017 | 66 | 2017 |
The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma B Moyo, SA Nicholson, PB Arbuthnot Virus research 212, 103-113, 2016 | 45 | 2016 |
Progress with developing use of gene editing to cure chronic infection with hepatitis B virus A Ely, B Moyo, P Arbuthnot Molecular therapy 24 (4), 671-677, 2016 | 40 | 2016 |
Site-specific post-translational surface modification of adeno-associated virus vectors using leucine zippers NN Thadani, J Yang, B Moyo, CM Lee, MY Chen, G Bao, J Suh ACS synthetic biology 9 (3), 461-467, 2020 | 9 | 2020 |
Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases SA Nicholson, B Moyo, PB Arbuthnot World journal of hepatology 7 (6), 859, 2015 | 7 | 2015 |
ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep 2017; 7 (1): 7401 T Scott, B Moyo, S Nicholson, M Maepa, K Watashi, A Ely | 5 | |
483. Epigenetic silencing of hepatitis B cccDNA in vitro and in vivo using AAV-delivered engineered repressor transcription activator-like effector B Moyo, S Nicholson, I Roelofse, C Crowther, K Bloom, C Mussolino, ... Molecular Therapy 23, S192, 2015 | 2 | 2015 |
Encapsulation of AAVs into protein vault nanoparticles as a novel solution to gene therapy’s neutralizing antibody problem LT Collins, W Beatty, B Moyo, M Alves-Bezerra, A Hurley, Q Lou, ZH Zhou, ... bioRxiv, 2023.11. 29.569229, 2023 | | 2023 |
Harnessing Multiparatopic Antibodies for Targeted Intracellular Therapeutic Delivery J Tan, K Kaeo, B Moyo, S Ludwig, G Bao, J Spangler 2023 AIChE Annual Meeting, 2023 | | 2023 |
Developing an Adeno-Associated Virus-Based Protein Display Platform for Modular Delivery of Gene Editing Machinery NN Thadani, J Yang, C Lee, B Moyo, B Kundu, X Gao, G Bao, J Suh MOLECULAR THERAPY 27 (4), 88-88, 2019 | | 2019 |
118. Inhibition of Hepatitis B Virus Replication In Vivo Following Delivery of Antiviral TALENs With Recombinant Adeno-Associated Viral Vectors S Nicholson, B Moyo, K Bloom, C Mussolino, T Cathomen, K Watashi, ... Molecular Therapy 23, S49, 2015 | | 2015 |